Palisades Capital

Palisades Therapeutics is a clinical-stage biotechnology company focused on the development of novel small molecule inhibitors for the treatment of aggressive cancers. The company's research centers on the Rho family of GTPases, which are critical regulators of cell signaling pathways involved in cancer cell proliferation, migration, and survival. Its lead therapeutic candidate, PT-101, is a targeted inhibitor that has been evaluated in early-stage clinical trials for indications such as acute myeloid leukemia (AML) and pancreatic cancer. Palisades Therapeutics operates as an affiliate of the investment firm Palisades Capital Management, leveraging specialized expertise to advance therapies for high-unmet-need malignancies.